2 FTSE 100 dividend stocks I’d avoid despite yielding more than 5%

These two FTSE 100 (INDEXFTSE: UKX) dividend growth stocks face uphill tasks, says Harvey Jones.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 dividend yield average is a thumping 4.5%, giving savers sweet relief from terminally low savings rates.

Some of the biggest dividend stocks offer even larger yields than that, which can really turbocharge your income. Here are two 5% yielders that caught my eye. I thought they might fit nicely in your Stocks and Shares ISA but on closer inspection, I’d approach with caution.

GlaxoSmithKline

Pharmaceuticals giant GlaxoSmithKline (LSE: GSK) is one of the most renowned FTSE 100 income stocks and that remains the case today. Its current forecast yield is 5.1%, with cover of 1.4. However, the Glaxo share price has underperformed horribly, and trades 3% lower than five years ago, whereas the index as a whole is up 12% over the same period.

Worse, the dividend has been frozen at 80p since 2015, and is expected to stay there for at least the next couple of years. Free cash flow fell by 50% to £165m in the three months to 31 March. Net debt of £22bn is another worry, although plans to spin off its consumer healthcare business in a £10bn joint venture with US rival Pfizer should reduce that.  

Glaxo has been hit by some blockbuster drugs going off patent, notably Advair, which has made up almost a quarter of revenues. Investing in R&D to strengthen its drugs pipeline has taken priority over rewarding shareholders, as management looks to get those revenues flowing again.

Pipeline panic

Glaxo has had some success on that front, recently reporting positive data for several potential new medicines in HIV and oncology, but it needs a lot more of this to fully convince.

CEO Emma Walmsley is pushing on with her turnaround plans and the company’s stock is yours for a relatively bargain price of just 14.3 times forecast earnings. This is low for Glaxo and Roland Head recently suggested that this might make a good entry point.

However, you are relying on Glaxo replenishing its pipelines and there are no guarantees on that score. The stock is riskier than I feel it should be.

Sainsbury’s

Investors in supermarket giant J Sainsbury (LSE: SBRY) have endured a dismal 12 months, its stock crashing 40% in that time. The grocery sector as a whole has struggled due to Brexit, squeezed incomes, Aldi and Lidl, but the Sainsbury’s share price has had by far the worst of it. Morrisons has fallen ‘only’ 18%, and Tesco just 5%.

Sainsbury’s was hit hard by the collapse of the Asda merger, which has offset the good news from its apparently successful takeover of Argos. This is forcing the group to focus on its core retail offering, and management is now looking to cut labour costs, boost buying terms and revamp its own label range to revive profits. 

Taking stock

I reckon Sainsbury’s has its work cut out as Brexit squeezes incomes and the German discounters continue to make strides. Debt is another concern. On the plus side, the 5.5% yield is tempting and looks solid with cover of 2.0.

Sainsbury’s stock also looks cheap trading at 11.2 times earnings. Earnings may pick up slightly going forward, and the share price might spike as investors finally decide it has been oversold. I can’t work up much enthusiasm for it though.

Harvey Jones has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Two white male workmen working on site at an oil rig
Investing Articles

As oil prices soar, is it time to buy Shell shares?

Christopher Ruane weighs some pros and cons of adding Shell shares to his ISA -- and explains why the oil…

Read more »

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

How much do you need in an ISA for £6,751 passive income a year in 2046?

Let's say an investor wanted a passive income in 20 years' time. How much cash would need be built up…

Read more »

Smiling black woman showing e-ticket on smartphone to white male attendant at airport
Investing Articles

Why isn’t the IAG share price crashing?

Harvey Jones expected the IAG share price to take an absolute beating during current Middle East hostilities. So why is…

Read more »

piggy bank, searching with binoculars
Growth Shares

1 UK share I’d consider buying and 1 I’d run away from on this market dip

In light of the recent stock market dip, Jon Smith outlines the various potential outcomes for a couple of different…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

AI may look like a bubble. But what about Rolls-Royce shares?

Bubble talk has been centred on some AI stocks lately. But Christopher Ruane sees risks to Rolls-Royce shares in the…

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

Will the BAE Systems share price soar 13% by this time next year?

BAE Systems' share price continues to surge as the Middle East crisis worsens. Royston Wild asks if the FTSE 100…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

Is this a once-in-a-decade chance to bag a 9.9% yield from Taylor Wimpey shares?

Taylor Wimpey shares have been hit by a volatile share price and cuts to the dividend. Harvey Jones holds the…

Read more »

Chalkboard representation of risk versus reward on a pair of scales
Investing Articles

Way up – or way down? This FTSE 250 share could go either way

Can this FTSE 250 share turn its fortunes around? Or has its day passed? Our writer looks at both sides…

Read more »